Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 16/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12999439 | 0.85 | KMT2A (0.42) | DHODHMAPT | |
| SCHEMBL15808931 | 0.83 | ALDH1A1 (0.48) | DHODHMAPTMAPK1 | |
| SCHEMBL15808930 | 0.83 | ALDH1A1 (0.48) | DHODHMAPTMAPK1 | |
| SCHEMBL15808812 | 0.81 | MAPT (0.47) | DHODHMAPTMAPK1 | |
| SCHEMBL15809515 | 0.80 | MAPT (0.44) | DHODHMAPTMAPK1 | |
| SCHEMBL15808811 | 0.80 | MAPT (0.44) | DHODHMAPTMAPK1 | |
| SCHEMBL7029112 | 0.80 | HTT (0.48) | DHODHMAPTMAPK1 | |
| SCHEMBL10253514 | 0.80 | DHODH (0.64) | DHODH | |
| SCHEMBL15809051 | 0.79 | MAPT (0.43) | DHODHMAPTMAPK1 | |
| SCHEMBL15022789 | 0.77 | NQO2 (0.48) | MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | CARNA BIOSCIENCES INC. (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226315-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | Carna Biosciences Inc. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311965-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | DSTYK, ABL1, EEF2K | DHODH 3711/4885MAPT 4766/4885MAPK1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.